Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA appro...

Full description

Saved in:
Bibliographic Details
Published in:Future Oncol
Main Authors: Zimmer, Alexandra S, Steinberg, Seth M, Smart, Dee Dee, Gilbert, Mark R, Armstrong, Terri S, Burton, Eric, Houston, Nicole, Biassou, Nadia, Gril, Brunilde, Brastianos, Priscilla K, Carter, Scott, Lyden, David, Lipkowitz, Stanley, Steeg, Patricia S
Format: Artigo
Language:Inglês
Published: Future Medicine Ltd 2020
Subjects:
Clinical Trial Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7270957/
https://ncbi.nlm.nih.gov/pubmed/32270710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0094
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items